May 2009
We have one of the largest life science portfolios in Europe, adding 4 - 6 early stage companies every year. Our model enables us to finance projects as well as bring researchers together with experts who can assist them.
We work with a network of experienced professionals, particularly in setting up development strategies (at the core of the business model). They assist researchers and hence allow them to remain concentrated in their scientific field. We clearly target commercial development, and our efforts to assist innovation require outstanding competitiveness.
Our firm's 300 investors come from both the public and the private sector which makes our model quite unique.
With full knowledge of the companies in our portfolio and their markets, we can readily make decisions. A highly operational model in addition to the knowledge we have acquired along the way, have lead to very exciting results. Starting the first seed investments as recently as 2003, we hope to conclude the first partnering deals in the next 1-2 years.
Can you share some success stories with us?
We are still quite young, but three of the companies in our portfolio already have products on the market; four have entered Phase II and six Phase I. I think we will have an opportunity to present some of them at EuroBiO, as we will partake in the event as speakers in the conference sessions as well as in EuroBiO one to one meetings.
Why are you participating in EuroBiO one to one meetings?
We need events that will facilitate our encounter with academia and companies. It is necessary to create "opportunities for projects". EuroBiO is certainly on the right track. Today, the stakes for Europe, if we wish to be successful lies in finding funds and talent that can transform innovation into a breakthrough product.
About Conny Bogentoft
PhD in Medicinal Chemistry and Associate Professor in Pharmaceutical Chemistry, Conny Bogentoft has acquired over 30 years of experience in the pharmaceutical industry, in senior R&D management positions and as a member of the Board of Directors of a number of companies, and has demonstrated his ability to successfully plan, implement and develop clinical and business strategies. Previous appointments include Vice President of Astra Arcus, President of Kabi Invent, Research Director at Aco Läkemedel and Chairman of the Swedish Academy of Pharmaceutical Sciences.
Our team will attend Bio in Atlanta next week. Come and meet us on the Eurasanté booth (n°1949) to know all about EuroBiO and optimize your participation.
You can make an appointment with our team by dialling the following numbers:
Zakaria El Asri: + 33 (0)6 77 43 13 89
Yassine Chirzad: + 33 (0)6 70 74 55 14 (valid only for the Bio event)
EuroBiO full pass: How to sign up?
Fill in your profile and view the files of the participants in the business convention and get ready upstream for your encounters!
You can sign up on
www.eurobio-event.com.
Biotech pharma deals in partnership with
